THE WOODLANDS, Texas and HUMMELSTOWN, Pa., March 17, 2026 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first of its kind cellular therapy that leverages the versatility and…
Read More
SIRPant Immunotherapeutics (now BobcatBio) to Participate in Wells Fargo Virtual Private Biotech Symposium See more here
Read More
SIRPant Immunotherapeutics (now BobcatBio) Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma See more here
Read More
SIRPant Immunotherapeutics (now BobcatBio) Strengthens Board of Directors with Appointment of Roger Sawhney, M.D. See more here
Read More
SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors See more here
Read More
SIRPant Immunotherapeutics (now BobcatBio) Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma See more here
Read More
SIRPant Immunotherapeutics (now BobcatBio) to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting See more here
Read More
SIRPant Immunotherapeutics (now BobcatBio) Appoints Jelle Kijlstra, MD, MBA as Chief Medical Officer
SIRPant Immunotherapeutics (now BobcatBio) Appoints Jelle Kijlstra, MD, MBA as Chief Medical Officer Accomplished healthcare executive brings extensive drug development and regulatory experience from global CRO and multiple pharmaceutical companies to SIRPant Immunotherapeutics Inc See more here
Read More
SIRPant Immunotherapeutics (now BobcatBio) Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy See more here
Read More